| abstract |
The present invention provides a method of measuring 2,2-dimethyl-N-((S) -6-oxo-6,7-dihydro by measuring the levels of biomarkers that are IL6 and / or IL8 present in biological samples obtained from a subject. The resistance of the subject to treatment with -5H-dibenzo [b, d] azin-7-yl) -N '-(2,2,3,3,3-pentafluoro-propyl) -malonamide It is about a method of measuring. In addition, the present invention relates to 2,2-dimethyl-N-((S) -6-oxo-6,7-dihydro-5H-dibenzo [b, d] azepine- in patients suffering from proliferative disorders. 7-yl) -N '-(2,2,3,3,3-pentafluoro-propyl) -malonamide and an anti-IL6 and / or anti-IL8 agent. . |